Universal or “pan-cancer” testing panels are broad and comprehensive; any patent meeting the criteria for breast cancer or colon cancer panel likely qualifies, yet patients are not doing so. They are vastly under-utilized.
DocWire News spoke with Dr. Sadie Debrozsi, of Evolent, about ways we can change this include being unified as a scientific community and working toward unifying policies.